Lv5
930 积分 2023-02-28 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1天前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial
1个月前
已完结
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
2个月前
已完结
Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial
2个月前
已完结
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
2个月前
已完结
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2个月前
已完结
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
4个月前
已完结
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
4个月前
已完结
Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
4个月前
已完结
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
4个月前
已完结
皖公网安备34019202002308
